Workflow
Securities Class - Action Lawsuit
icon
Search documents
DEADLINE TOMORROW: Berger Montague Advises Elevance Health (NYSE: ELV) Investors to Contact the Firm Before July 11, 2025
Prnewswire· 2025-07-10 15:19
PHILADELPHIA, July 10, 2025 /PRNewswire/ -- Berger Montague PC advises investors that a securities class action lawsuit has been filed against Elevance Health, Inc. ("Elevance" or the "Company") (NYSE: ELV) on behalf of purchasers of Elevance securities between April 18, 2024 through October 16, 2024, inclusive (the "Class Period").Investor Deadline: Investors who purchased or acquired Elevance securities during the Class Period may, no later than JULY 11, 2025, seek to be appointed as a lead plaintiff repr ...
Hims & Hers Health, Inc. (HIMS) Faces Securities Class Actions After Novo Nordisk Cancels Partnership Over “Deceptive” Marketing of Wegovy – Hagens Berman
GlobeNewswire News Room· 2025-07-09 21:19
SAN FRANCISCO, July 09, 2025 (GLOBE NEWSWIRE) -- On June 25, 2025, two securities class action lawsuits were filed against Hims & Hers Health, Inc. (NYSE: HIMS) and certain of the company’s executives. Sookdeo v. Hims & Hers Health, Inc., et al., No. 3:25-cv-05315 (N.D. Cal.) and Yaghsizian v. Hims & Hers Health, Inc. et al., No. 3:25-cv-05321 (N.D. Cal.). Together, the cases seek to represent investors who purchased or otherwise acquired Hims & Hers securities between April 29, 2025 and June 23, 2025. The ...
Class Action Announcement for Sarepta Therapeutics, Inc. (SRPT): Kessler Topaz Meltzer & Check, LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Sarepta Therapeutics, Inc.
Prnewswire· 2025-07-08 20:12
RADNOR, Pa., July 8, 2025 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Sarepta Therapeutics, Inc. ("Sarepta") (NASDAQ: SRPT) on behalf of those who purchased or otherwise acquired Sarepta securities between June 22, 2023, and June 24, 2025, inclusive (the "Class Period"). The lead plaintiff deadline is August 25, 2025.CONTACT KESSLER TOPAZ MELTZER & CHECK, LLP:If you suffered Sarepta losses, ...
CODI DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Compass Diversified Holdings Investors with Losses in Excess of $100K to Secure Counsel Before Important July 8 Deadline in Securities Class Action First Filed by the Firm – CODI
GlobeNewswire News Room· 2025-07-08 16:09
NEW YORK, July 08, 2025 (GLOBE NEWSWIRE) -- WHY: New York, N.Y., July 8, 2025. Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Compass Diversified Holdings (NYSE: CODI) between March 1, 2023, and May 7, 2025, both dates inclusive (the “Class Period”), of the important July 8, 2025 lead plaintiff deadline in the securities class action first filed by the Firm. SO WHAT: If you purchased Compass securities you may be entitled to compensation without payment of any out of ...
DEADLINE THIS WEEK: Berger Montague Advises Elevance Health (NYSE: ELV) Investors to Contact the Firm Before July 11, 2025
Prnewswire· 2025-07-07 20:06
PHILADELPHIA, July 7, 2025 /PRNewswire/ -- Berger Montague PC advises investors that a securities class action lawsuit has been filed against Elevance Health, Inc. ("Elevance" or the "Company") (NYSE: ELV) on behalf of purchasers of Elevance securities between April 18, 2024 through October 16, 2024, inclusive (the "Class Period").Investor Deadline: Investors who purchased or acquired Elevance securities during the Class Period may, no later than JULY 11, 2025, seek to be appointed as a lead plaintiff repre ...
HIMS Investor Alert: Kessler Topaz Meltzer & Check, LLP Urges HIMS Investors with Losses to Contact the Firm
GlobeNewswire News Room· 2025-07-06 17:17
Core Viewpoint - Securities class action lawsuits have been filed against Hims & Hers Health, Inc. for allegedly making false and misleading statements regarding the company's business practices and safety concerns related to its products [1][2]. Group 1: Allegations Against Hims & Hers - The complaints allege that Hims & Hers engaged in deceptive promotion and selling of illegitimate versions of Wegovy, which posed risks to patient safety [2]. - It is claimed that there was a substantial risk of termination of Hims & Hers' collaboration with Novo Nordisk due to these practices [2]. - The positive statements made by the company regarding its business and operations were deemed materially misleading and lacked a reasonable basis [2]. Group 2: Legal Process for Investors - Investors in Hims & Hers have until August 25, 2025, to seek appointment as lead plaintiff representatives in the class action [3]. - A lead plaintiff acts on behalf of all class members and is typically the investor or group of investors with the largest financial interest [3]. - The decision to serve as a lead plaintiff does not affect an investor's ability to share in any recovery from the lawsuit [3]. Group 3: Firm Background - Kessler Topaz Meltzer & Check, LLP is known for prosecuting class actions and has a reputation for recovering billions for victims of corporate misconduct [4]. - The firm aims to protect investors and consumers from fraud and negligence by businesses [4].
DMRC DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Digimarc Corporation Investors with Losses in Excess of $100K to Secure Counsel Before Important July 8 Deadline in Securities Class Action – DMRC
GlobeNewswire News Room· 2025-07-05 18:42
Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Digimarc Corporation during the specified class period of the upcoming lead plaintiff deadline on July 8, 2025, and the potential for compensation without out-of-pocket costs [1][2]. Group 1: Class Action Details - A class action lawsuit has been filed against Digimarc Corporation, and investors who wish to serve as lead plaintiff must act by July 8, 2025 [2]. - The lawsuit alleges that Digimarc made false and misleading statements regarding its business operations, specifically about a large commercial partner not renewing a significant contract, which adversely affected subscription and annual recurring revenue [4]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in recovering hundreds of millions for investors [3]. - The firm has been recognized for its leadership in securities class action settlements, achieving the largest settlement against a Chinese company at the time and ranking in the top four for settlements since 2013 [3].
DV DEADLINE: ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages DoubleVerify Holdings, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – DV
GlobeNewswire News Room· 2025-07-04 13:06
Core Viewpoint - Rosen Law Firm is reminding investors who purchased DoubleVerify Holdings, Inc. common stock during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought DoubleVerify common stock between November 10, 2023, and February 27, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by July 21, 2025 [3]. - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [6]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting their own success in recovering significant amounts for investors [4]. - The firm has been recognized for its leadership in securities class action settlements, achieving the largest settlement against a Chinese company at the time and securing over $438 million for investors in 2019 alone [4]. Group 3: Allegations Against DoubleVerify - The lawsuit alleges that DoubleVerify made false and misleading statements regarding its business operations, including the shift of customer ad spending to closed platforms where its capabilities were limited [5]. - It is claimed that DoubleVerify's high-margin advertising optimization services faced significant challenges in monetization due to the high costs and time required for technology development on closed platforms [5]. - The lawsuit also points out that DoubleVerify overbilled customers for ad impressions served to bots and that its risk disclosures were misleading, leading to investor damages when the true situation was revealed [5].
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Sarepta Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SRPT
GlobeNewswire News Room· 2025-07-04 12:23
NEW YORK, July 04, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) between June 22, 2023 and June 24, 2025, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 25, 2025. SO WHAT: If you purchased Sarepta securities during the ...
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages PepGen Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – PEPG
GlobeNewswire News Room· 2025-07-03 22:10
Core Viewpoint - Rosen Law Firm is reminding investors who purchased PepGen Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline on August 8, 2025, for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who bought PepGen securities between March 7, 2024, and March 3, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by the deadline [2]. - The Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [3]. Group 2: Case Allegations - The lawsuit alleges that PepGen made false and misleading statements regarding the effectiveness and safety of PGN-EDO51, as well as the CONNECT2 study's suitability for FDA approval [4]. - It is claimed that due to these misrepresentations, PepGen was likely to halt the CONNECT2 study, leading to overstated clinical, regulatory, and commercial prospects for PGN-ED051 [4]. - The lawsuit asserts that when the true information became public, investors suffered damages as a result of the misleading statements [4]. Group 3: Rosen Law Firm's Credentials - The Rosen Law Firm has a strong reputation in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time [3]. - The firm was ranked No. 1 by ISS Securities Class Action Services for the number of settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions for investors [3]. - In 2019, the firm secured over $438 million for investors, showcasing its effectiveness in litigation [3].